EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AURKA / PLK1 / CDC25C Axis as a Novel Therapeutic Target in INI1 ‐Deficient Epithelioid Sarcoma

Akitomo Inoue, Hidetatsu Outani, Yoshinori Imura iD, Sho Nakai iD, Haruna Takami, Yuki Kotani, Hirokazu Mae, Seiji Okada

Cancer Science · 2025

DOI: 10.1111/cas.16438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Akitomo Inoue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Aurora Kinase A, Proto-Oncogene Proteins, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective therapeutic strategies for epithelioid sarcoma (EpS), a high‐grade soft tissue sarcoma characterized by loss of integrase interactor 1 (INI1), have not yet been developed. The present study therefore investigated the association between INI1 loss and upregulation of the aurora kinase A (AURKA)/polo‐like kinase 1 (PLK1)/cell division cycle 25C (CDC25C) axis, as well as the therapeutic relevance of this axis in EpS. Notably, our findings showed that the reintroduction of INI1 in VA‐ES‐BJ cells significantly reduced proliferation, mitigated tumorigenicity, and negatively regulated the expression of AURKA and its downstream effectors, as well as the activation of PLK1 and CDC25C. These results suggest that INI1 deficiency enhanced EpS growth by upregulating the AURKA/PLK1/CDC25C axis. AURKA silencing using siRNAs inhibited VA‐ES‐BJ and Asra‐EPS cell proliferation by inactivating PLK1 and CDC25C. Alisertib, a selective AURKA inhibitor, exerted markedly greater antiproliferative effects on EpS cells than on normal human dermal fibroblasts, and these effects were dependent on INI1 deficiency. Inhibition of AURKA activity by alisertib induced G2/M cell cycle arrest and apoptosis via the inactivation of AURKA downstream effectors in EpS cells. Alisertib also significantly decreased VA‐ES‐BJ xenograft tumor growth. Taken together, our findings revealed that INI1 loss in EpS cells enhances the expression of AURKA and its downstream effectors and persistently activates PLK1 and CDC25C mediated by AURKA, making the cells reliant on the AURKA/PLK1/CDC25C axis. Therefore, the AURKA/PLK1/CDC25C axis activated by INI1 deficiency could serve as a novel therapeutic target for this devastating disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Cycle ProteinsAurora Kinase AProto-Oncogene ProteinsProtein Serine-Threonine KinasesSMARCB1 ProteinSarcomacdc25 PhosphatasesPolo-Like Kinase 1HumansAnimalsMiceCell Line, TumorCell ProliferationPyrimidinesAzepinesMice, NudeXenograft Model Antitumor AssaysGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

alisertibaurora kinase Aepithelioid sarcomapolo‐like kinase 1soft tissue sarcoma

Substanzen

Polo-Like Kinase 1Cell Cycle ProteinsAurora Kinase AProto-Oncogene ProteinsProtein Serine-Threonine KinasesAURKA protein, humanSMARCB1 ProteinSMARCB1 protein, humancdc25 PhosphatasesCDC25C protein, human

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

ORCID-Profile: Yoshinori Imura, Sho Nakai

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Inoue, A., Outani, H., Imura, Y., Nakai, S., Takami, H., Kotani, Y., Mae, H., & Okada, S. (2025). AURKA / PLK1 / CDC25C Axis as a Novel Therapeutic Target in INI1 ‐Deficient Epithelioid Sarcoma. Cancer Science. https://doi.org/10.1111/cas.16438

Vancouver

Inoue A, Outani H, Imura Y, Nakai S, Takami H, Kotani Y, et al. AURKA / PLK1 / CDC25C Axis as a Novel Therapeutic Target in INI1 ‐Deficient Epithelioid Sarcoma. Cancer Science. 2025. doi:10.1111/cas.16438

BibTeX
@article{Inoue2025,
  author = {Inoue, Akitomo and Outani, Hidetatsu and Imura, Yoshinori and Nakai, Sho and Takami, Haruna and Kotani, Yuki and Mae, Hirokazu and Okada, Seiji},
  title = {AURKA / PLK1 / CDC25C Axis as a Novel Therapeutic Target in INI1 ‐Deficient Epithelioid Sarcoma},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.16438}
}
Kostenlos starten →